Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2013. The report details a specific share repurchase transaction executed on June 17, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 414,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,699.25 pence per share; lowest price paid was 1,681.50 pence per share.
- Treasury Holdings (Settled): 510,293,512 shares (9.40% of total issued share capital).
- Treasury Holdings (Including Unsettled): 511,602,512 shares (10.40% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,919,456,132 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 414,000 shares on June 17, 2013. Consequently, the percentage of total voting rights held in Treasury increased to 10.40% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (510,293,512 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.40% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Note that the 4,919,456,132 shares in issue (excluding Treasury) serve as the denominator for shareholder notification requirements under FCA rules.